Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor-Reference-Cited by-同舟云学术

Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor

Published:2014-09-17 Issue:8 Volume:34 Page:787-793
ISSN:0733-2467
Container-title:Neurourology and Urodynamics
language:en
Short-container-title:Neurourol. Urodynam.

Author:

Füllhase C.¹²,Hennenberg M.³,Sandner P.⁴⁵,Strittmatter F.³,Niedworok C.⁶,Bauer R.M.³,Gratzke C.³,Soler R.⁷,Stief C.³,Andersson K.E.⁸

Affiliation:

1. Department of Urology; University of Rostock; Rostock Germany

2. Walter Brendel Center for Experimental Medicine; Ludwig-Maximilians-University; Munich Germany

3. Department of Urology; Ludwig-Maximilians-University; Munich Germany

4. Bayer Health Care; Global Drug Discovery; Common Mechanism Research; Wuppertal Germany

5. Institute of Pharmacology; Hannover Medical School; Hannover Germany

6. Department of Urology; University of Essen; Essen Germany

7. Division of Urology; Federal University of São Paulo; São Paulo Brazil

8. Institute for Regenerative Medicine; Wake Forest University; Winston-Salem North Carolina

Publisher

Wiley

Subject

Urology,Neurology (clinical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/nau.22665/fullpdf

Reference21 articles.

1. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction;Oelke;Eur Urol,2013

2. Guidelines on male sexual dysfunction: Erectile dysfunction and premature ejaculation;Hatzimouratidis;Eur Urol,2010

3. Treating erectile dysfunction when PDE5 inhibitors fail;McMahon;BMJ,2006

4. Short-term efficacy and long-term compliance/treatment failure of the alpha1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia;Masumori;Scand J Urol Nephrol,2007

5. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia;Giuliano;Eur Urol,2013

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Local Injection of Stem Cells Can Be a Potential Strategy to Improve Bladder Dysfunction after Outlet Obstruction in Rats;International Journal of Molecular Sciences;2024-07-30

2. Nitric oxide signaling pathways in the normal and pathological bladder: Do they provide new pharmacological pathways?—ICI‐RS 2023;Neurourology and Urodynamics;2023-10-30

3. Soluble guanylate cyclase mediates the relaxation of healthy and inflamed bladder smooth muscle by aqueous nitric oxide;Frontiers in Physiology;2023-09-04

4. Treatment with the soluble guanylate cyclase activator BAY 60-2770 restores in vitro bladder contractile responses in a rat model of chronic prostatitis;Continence;2022-12

5. Identification of hub biomarkers and exploring the roles of immunity, M6A, ferroptosis, or cuproptosis in rats with diabetic erectile dysfunction;Andrology;2022-08-24